{"id":2693,"date":"2025-07-02T09:30:00","date_gmt":"2025-07-02T08:30:00","guid":{"rendered":"https:\/\/patworld.com\/us\/?p=2693"},"modified":"2026-01-05T17:06:20","modified_gmt":"2026-01-05T17:06:20","slug":"pharmaceutical-patent-exclusivity-francis-tierney","status":"publish","type":"post","link":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/","title":{"rendered":"Meet the IP Professional: Francis Tierney \u2013 Exclusivity in Pharma and Navigating the Life Sciences Patent Landscape"},"content":{"rendered":"\n<p>When it comes to securing exclusivity in the life sciences sector, few bring the depth of insight and strategic clarity that Francis Tierney offers. A qualified UK and European patent attorney since the 1990s, Francis blends decades of in-house experience with a boutique advisory approach that gives life sciences companies a genuine edge\u2014particularly in pharmaceuticals and small molecule therapeutics. In this article PatWorld discusses with Francis Exclusivity in Pharma, and Navigating the Life Sciences Patent Landscape. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\">From In-House to Boutique: A Unique Perspective<\/h2>\n\n\n\n<p>Francis began his IP career in-house, spending nearly three decades advising on agrochemical and pharmaceutical innovations before moving into private practice. This &#8220;poacher turned gamekeeper&#8221; transition, as he jokingly puts it, equips him with an intuitive understanding of how clients operate and what they truly need from their IP counsel.<\/p>\n\n\n\n<p>Now at <a href=\"https:\/\/patent.boutique\/\" target=\"_blank\" rel=\"noreferrer noopener\">Patent Boutique<\/a>, he works closely with clients on prosecution, opposition, appeal work, due diligence, and strategic portfolio development. His tailored, hands-on approach is a hallmark of the firm.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Five Pillars of Patent Strategy in Pharma<\/h2>\n\n\n\n<p>Francis sees five key IP considerations for life sciences companies today:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Confidentiality:<\/strong> With increased pressure to publish and attract investors, ensuring non-disclosure before filing is vital.<\/li>\n\n\n\n<li><strong>Timing of Filings:<\/strong> Filing too early can lead to protection ending earlier during peak sales; too late, and companies risk being scooped.<\/li>\n\n\n\n<li><strong>Collaboration with R&amp;D:<\/strong> Patent attorneys need to work closely with research teams to react quickly to emerging data and shape strategy in real time.<\/li>\n\n\n\n<li><strong>Market Awareness:<\/strong> Limited budgets mean companies must prioritise filings in jurisdictions most critical to commercial success.<\/li>\n\n\n\n<li><strong>AI:<\/strong> Keeping abreast of developments in, and the increasing capabilities of, AI.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Getting Patent Drafting Right<\/h2>\n\n\n\n<p>Drafting for small molecules brings its own hazards. \u201cIf you draft too broadly, not only might your claims be rejected, but you risk creating your own most damaging prior art,\u201d Francis warns. He emphasises the importance of including strong biological data\u2014especially for markets like China\u2014and ensuring that patents will remain enforceable 20+ years down the line, particularly when linked to SPCs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">US vs. Europe: Avoiding a Common Pitfall<\/h2>\n\n\n\n<p>One of the most frequent issues Francis sees is US-based companies underestimating global disclosure rules. \u201cThere\u2019s a grace period in the US, but not in Europe. Smaller companies often publish during the priority year, which can be problematic for later filings,\u201d he explains.<\/p>\n\n\n\n<p>He also notes how different legal frameworks\u2014such as the EPO\u2019s problem-solution approach versus the US&#8217;s obviousness standard\u2014can yield very different outcomes from the same prior art.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Early-Stage Advice: Flexible, Focused, and Fast<\/h2>\n\n\n\n<p>Emerging biotech companies often need more tailored support, especially when balancing speed, disclosure, and credibility for investors. Francis helps them navigate this by streamlining prosecution strategies and ensuring they have grantable, meaningful patents to support licensing or M&amp;A activities.<\/p>\n\n\n\n<p>\u201cEstablished pharma companies have structured IP processes. Start-ups don\u2019t\u2014so we help them build systems and strategies that are credible and cost-effective,\u201d he says.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Patent Portfolios as Deal Enablers<\/h2>\n\n\n\n<p>Whether supporting collaborations or preparing for acquisition, Francis views robust IP portfolios as central. \u201cYou need to show what you\u2019ve got, but also what you might be developing. Priority filings before a deal are key to demonstrating value,\u201d he advises.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">AI in Drug Discovery: A New Frontier, with Caveats<\/h2>\n\n\n\n<p>Francis acknowledges AI as a potential game-changer in small molecule R&amp;D, but with caution. \u201cIf AI knows everything, where\u2019s the inventive step?\u201d he asks. He sees a possible future where narrower, more focused patent claims become the norm due to more precise AI targeting\u2014but also where validity could well be questioned if algorithms become standardised tools.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A Call for Change: Grace Period Reform<\/h2>\n\n\n\n<p>If he could change one thing in the UK or EU IP landscape, Francis would introduce a broader grace period. \u201cIt would protect researchers from the kind of accidental disclosures that can destroy patentability. A safety net\u2014not to rely on, but to support honest mistakes.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Boutique Advantage<\/h2>\n\n\n\n<p>At Patent Boutique, Francis and his colleagues offer flexibility, cost transparency, and a collaborative approach. \u201cWe were cloud-based from the start, so our clients benefit from seamless document transfer, real-time communication, and scalable support,\u201d he notes. Clients also gain access to a wider network of trusted attorneys\u2014competency, not size or shine, is what counts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Outside the Office: Gardening and Grandkids<\/h2>\n\n\n\n<p>Beyond the world of SPCs and claim drafting, Francis is a proud grandfather and a keen (and increasingly enthusiastic) gardener. \u201cIt\u2019s such a contrast to patent law\u2014where you wait years for a result. In the garden, you plant something and within weeks, there\u2019s colour, texture, and reward,\u201d he says. His latest pride? A set of stunning Alstroemeria \u2014particularly a variety called <em>Indian Summer<\/em>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>Connect with Francis Tierney<\/strong><br>\ud83d\udd17 <a href=\"https:\/\/www.linkedin.com\/in\/francis-j-tierney\/\" target=\"_blank\" rel=\"noreferrer noopener\">Francis Tierney on LinkedIn<\/a><br>\ud83d\udd17 <a href=\"https:\/\/patent.boutique\/\" target=\"_blank\" rel=\"noreferrer noopener\">Patent Boutique<\/a> \u2013 A specialist firm offering high-level, strategic patent services tailored to life sciences and beyond.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>P.S. How PatWorld Supports Patent Attorneys Like Francis<\/strong><br>PatWorld supports IP professionals with expert-led <strong>Patent, Trademark, and Design Search services<\/strong>. Whether you&#8217;re advising clients on exclusivity strategies, preparing for prosecution or opposition, or managing complex portfolios, our tailored search solutions deliver the clarity and confidence you need to move forward.<\/p>\n\n\n\n<p>Order a search today at<a href=\"https:\/\/patworld.com\/us\/order-a-search\/\">\u00a0patworld.com\/us\/order-a-search.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>When it comes to securing exclusivity in the life sciences sector, few bring the depth of insight and strategic clarity that Francis Tierney offers. A qualified UK and European patent attorney since the 1990s, Francis blends decades of in-house experience with a boutique advisory approach that gives life sciences companies a genuine edge\u2014particularly in pharmaceuticals [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2694,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[236,1],"tags":[283,189,278,165,150,297,32],"class_list":["post-2693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-meet-the-ip-professional","category-news","tag-commercial-insight","tag-francis-tierney","tag-ip-strategist","tag-life-sciences","tag-patent-attorney","tag-patent-boutique","tag-patents"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney<\/title>\n<meta name=\"description\" content=\"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney\" \/>\n<meta property=\"og:description\" content=\"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/\" \/>\n<meta property=\"og:site_name\" content=\"PatWorld US\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T08:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T17:06:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"2117\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"sueleslie\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"sueleslie\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/\"},\"author\":{\"name\":\"sueleslie\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/#\\\/schema\\\/person\\\/9ff82671b8df0bde6fa8d32e7530af93\"},\"headline\":\"Meet the IP Professional: Francis Tierney \u2013 Exclusivity in Pharma and Navigating the Life Sciences Patent Landscape\",\"datePublished\":\"2025-07-02T08:30:00+00:00\",\"dateModified\":\"2026-01-05T17:06:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/\"},\"wordCount\":892,\"image\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/patworld.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/16\\\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg\",\"keywords\":[\"Commercial Insight\",\"Francis Tierney\",\"IP Strategist\",\"Life Sciences\",\"Patent Attorney\",\"Patent Boutique\",\"patents\"],\"articleSection\":[\"Meet the IP Professional\",\"News\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/\",\"url\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/\",\"name\":\"Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/patworld.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/16\\\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg\",\"datePublished\":\"2025-07-02T08:30:00+00:00\",\"dateModified\":\"2026-01-05T17:06:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/#\\\/schema\\\/person\\\/9ff82671b8df0bde6fa8d32e7530af93\"},\"description\":\"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#primaryimage\",\"url\":\"https:\\\/\\\/patworld.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/16\\\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/patworld.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/16\\\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg\",\"width\":2560,\"height\":2117,\"caption\":\"Pharma patent exclusivity strategy- Francis Tierney - Patent Attorney - Patent Boutique\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/pharmaceutical-patent-exclusivity-francis-tierney\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/patworld.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meet the IP Professional: Francis Tierney \u2013 Exclusivity in Pharma and Navigating the Life Sciences Patent Landscape\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/patworld.com\\\/us\\\/\",\"name\":\"PatWorld US\",\"description\":\"Expert IP Research Services\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/patworld.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/patworld.com\\\/us\\\/#\\\/schema\\\/person\\\/9ff82671b8df0bde6fa8d32e7530af93\",\"name\":\"sueleslie\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g\",\"caption\":\"sueleslie\"},\"url\":\"https:\\\/\\\/patworld.com\\\/us\\\/news\\\/author\\\/sueleslie\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney","description":"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/","og_locale":"en_GB","og_type":"article","og_title":"Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney","og_description":"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.","og_url":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/","og_site_name":"PatWorld US","article_published_time":"2025-07-02T08:30:00+00:00","article_modified_time":"2026-01-05T17:06:20+00:00","og_image":[{"width":2560,"height":2117,"url":"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg","type":"image\/jpeg"}],"author":"sueleslie","twitter_card":"summary_large_image","twitter_misc":{"Written by":"sueleslie","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#article","isPartOf":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/"},"author":{"name":"sueleslie","@id":"https:\/\/patworld.com\/us\/#\/schema\/person\/9ff82671b8df0bde6fa8d32e7530af93"},"headline":"Meet the IP Professional: Francis Tierney \u2013 Exclusivity in Pharma and Navigating the Life Sciences Patent Landscape","datePublished":"2025-07-02T08:30:00+00:00","dateModified":"2026-01-05T17:06:20+00:00","mainEntityOfPage":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/"},"wordCount":892,"image":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#primaryimage"},"thumbnailUrl":"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg","keywords":["Commercial Insight","Francis Tierney","IP Strategist","Life Sciences","Patent Attorney","Patent Boutique","patents"],"articleSection":["Meet the IP Professional","News"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/","url":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/","name":"Pharmaceutical Patent Exclusivity: Insights from IP Expert Francis Tierney","isPartOf":{"@id":"https:\/\/patworld.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#primaryimage"},"image":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#primaryimage"},"thumbnailUrl":"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg","datePublished":"2025-07-02T08:30:00+00:00","dateModified":"2026-01-05T17:06:20+00:00","author":{"@id":"https:\/\/patworld.com\/us\/#\/schema\/person\/9ff82671b8df0bde6fa8d32e7530af93"},"description":"Explore expert insights from Francis Tierney on pharmaceutical patent exclusivity strategies and key IP challenges in the life sciences sector.","breadcrumb":{"@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#primaryimage","url":"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg","contentUrl":"https:\/\/patworld.com\/us\/wp-content\/uploads\/sites\/16\/Francis-Tierney-Patent-Attorney-Patent-Boutique-scaled.jpg","width":2560,"height":2117,"caption":"Pharma patent exclusivity strategy- Francis Tierney - Patent Attorney - Patent Boutique"},{"@type":"BreadcrumbList","@id":"https:\/\/patworld.com\/us\/news\/pharmaceutical-patent-exclusivity-francis-tierney\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/patworld.com\/us\/"},{"@type":"ListItem","position":2,"name":"Meet the IP Professional: Francis Tierney \u2013 Exclusivity in Pharma and Navigating the Life Sciences Patent Landscape"}]},{"@type":"WebSite","@id":"https:\/\/patworld.com\/us\/#website","url":"https:\/\/patworld.com\/us\/","name":"PatWorld US","description":"Expert IP Research Services","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/patworld.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/patworld.com\/us\/#\/schema\/person\/9ff82671b8df0bde6fa8d32e7530af93","name":"sueleslie","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f637d340d8ae5f01e32a5b588c7d45a124a50a3e7b4a5cd02aef88ac3e24c8a?s=96&d=mm&r=g","caption":"sueleslie"},"url":"https:\/\/patworld.com\/us\/news\/author\/sueleslie\/"}]}},"_links":{"self":[{"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/posts\/2693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/comments?post=2693"}],"version-history":[{"count":0,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/posts\/2693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/media\/2694"}],"wp:attachment":[{"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/media?parent=2693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/categories?post=2693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patworld.com\/us\/wp-json\/wp\/v2\/tags?post=2693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}